Prescription Errors with Cytotoxic Drugs and the Inadequacy of Existing Classifications

Slama, Cyril; Jerome, J Schentag; Jacquot, C.; Bonan, Brigitte

doi:10.1007/s11096-005-6034-x

Cited by 22 publications

(29 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The rate of interventions in the present study, 22% during prescription screening and 4% during drug release, was higher than the rate of medication errors identified in chemotherapy prescription orders reported in the literature 9,11. Markert et al reported a chemotherapy error in 17.1% of received chemotherapy orders9, while Slama et al reported a prescribing error in 12% of the received chemotherapy orders 11.…”

Section: Discussioncontrasting

confidence: 72%

“…Markert et al reported a chemotherapy error in 17.1% of received chemotherapy orders9, while Slama et al reported a prescribing error in 12% of the received chemotherapy orders 11. However, the majority of errors in the described studies, 50.9% and 74%, respectively, were related to problem categories not included herein: missing a patient’s informed consent; and physicochemical incompatibilities.…”

Section: Discussionmentioning

confidence: 88%

“…Pharmacists’ interventions on prescribed chemotherapy observed on the wards and good and accurate risk management procedures in the dispensing of chemotherapy doses, such as the use of pre-written chemotherapy prescriptions, may have lowered the number of interventions needed as confirmed in the literature 4,9–11,14,22…”

Section: Discussionmentioning

confidence: 91%

“…However, the same cannot be said of the clinical role of pharmacists. Although this role has been described to some extent in the Competency Framework for Specialist Oncology Pharmacists of the British Oncology Pharmacists Association and in the German Quality Standard for the Pharmacy Oncology Service as well as emphasised in numerous studies, the clinical services provided by pharmacists in chemotherapy dose dispensing are not standardised across Europe 7–11. This may lead to substantial variation in the quality of patient care.…”

Section: Introductionmentioning

confidence: 99%

“…The implementation and benefits of these services have been described in several reports;4,9–12 however, pharmacists’ contribution to patient care is rarely assessed. Only a recent report of the British National Confidential Enquiry into Patient Outcome and Death (NCEPOD) provided evidence on the extent of pharmacists’ contribution to patient outcomes 11. The report analysed the treatment of cancer patients who had died within the first 30 days after receiving systemic chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Evaluation of clinical interventions made by pharmacists in chemotherapy preparation

Knez¹,

Laaksonen²,

Duggan³

2010

Radiology and Oncology

View full text Add to dashboard Cite

BackgroundCancer drugs are high risk drugs and medication errors in their prescribing, preparation and administration have serious consequences, including death. The importance of a multidisciplinary approach and the benefits of pharmacists’ contribution to cancer treatment to minimise risk have been established. However, the impact of services provided by pharmacists to cancer patient care is poorly studied. This study explored the clinical interventions made by pharmacists in dispensing of chemotherapy doses, and evaluated pharmacists’ contribution to patient care.MethodsPharmacists at the Chemotherapy Preparation Unit at a tertiary cancer centre in London were shadowed by two research pharmacists during the clinical screening of chemotherapy prescriptions and release of prepared drugs. An expert panel of pharmacy staff rated the clinical significance of the recorded interventions.ResultsTwenty-one pharmacists’ interventions were recorded during the screening or releasing of 130 prescriptions or drugs. “Drug and therapy” (38%), “clerical” (22%) and “dose, frequency and duration” (19%) related problems most often required an intervention, identifying areas in chemotherapy prescribing that need improvement. The proposed recommendations were implemented in 86% of the cases. Many recorded interventions (48%) were ranked to have had a “very significant” influence on patient care.ConclusionClinical interventions made by pharmacists had a significant impact on patient care. The integration of pharmacists’ technical and clinical roles into dispensing of chemotherapy doses is required for providing high-quality cancer services.

show abstract

Section: Discussioncontrasting

confidence: 72%

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Evaluation of clinical interventions made by pharmacists in chemotherapy preparation

Knez¹,

Laaksonen²,

Duggan³

2010

Radiology and Oncology

View full text Add to dashboard Cite

show abstract

Terms used in patient safety related to medication: a literature review

Pintor-Mármol

Baena

Fajardo

et al. 2012

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

Minimising treatment-associated risks in systemic cancer therapy

et al. 2007

View full text Add to dashboard Cite

Aim of the review To review the consequences of drug-related problems (DRP) in systemic cancer therapy and identify specific contributions of the pharmacist to minimise treatment-associated risks. Method Searches in PubMed, Embase and the Cochrane Library were conducted. Bibliographies of retrieved articles were examined for additional references. Only papers in English between 1980 and 2007 were included. Results In systemic cancer therapy there is an enormous potential for DRP due to the high toxicity and the complexity of most therapeutic regimens. The most frequently reported DRP can be classified into adverse effects, drug-drug interactions, medication errors, and non-adherence. Pharmacists have enhanced efforts to assure quality and safety in systemic cancer therapy together with other health care providers. In consequence, oncology pharmacy has evolved as a novel specialist discipline. The endeavour to merge and coordinate individual activities and services of the pharmacist has led to pharmaceutical care concepts which aim at offering novel solutions to the various DRP. Conclusion Pharmaceutical care for cancer patients should be developed within research projects and integrated into disease management programs in order to ensure broad implementation.

show abstract

Prescription Errors with Cytotoxic Drugs and the Inadequacy of Existing Classifications

Cited by 22 publications

References 10 publications

Evaluation of clinical interventions made by pharmacists in chemotherapy preparation

Evaluation of clinical interventions made by pharmacists in chemotherapy preparation

Terms used in patient safety related to medication: a literature review

Minimising treatment-associated risks in systemic cancer therapy

Contact Info

Product

Resources

About